{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=telmisartan&page=2", "query": { "intervention": "telmisartan", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=telmisartan&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T15:51:02.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04743063", "title": "Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Failure, Systolic", "Frailty" ], "interventions": [ { "name": "sacubitril/valsartan", "type": "DRUG" }, { "name": "Angiotensin II Receptor Blockers", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 40000, "start_date": "2021-01-14", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2021-02-15", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04743063" }, { "nct_id": "NCT00153101", "title": "Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cardiovascular Diseases" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" }, { "name": "Combination of Telmisartan and Ramipril", "type": "DRUG" }, { "name": "Ramipril", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 31546, "start_date": "2001-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 100, "location_summary": "Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00153101" }, { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" }, { "nct_id": "NCT04518293", "title": "Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg", "type": "DRUG" }, { "name": "telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg", "type": "DRUG" }, { "name": "Telmisartan 20 mg/amlodipine 2.5 mg", "type": "DRUG" }, { "name": "telmisartan 40 mg/amlodipine 5 mg", "type": "DRUG" }, { "name": "Telmisartan 20 mg/indapamide 1.25 mg", "type": "DRUG" }, { "name": "telmisartan 40 mg/indapamide 2.5 mg", "type": "DRUG" }, { "name": "Amlodipine 2.5 mg/indapamide 1.25 mg", "type": "DRUG" }, { "name": "amlodipine 5 mg/indapamide 2.5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Medicines PTY Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1385, "start_date": "2021-07-09", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "South Gate", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518293" }, { "nct_id": "NCT04360551", "title": "Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Telmisartan 40mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-07-01", "completion_date": "2022-04-26", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT04360551" }, { "nct_id": "NCT00981526", "title": "Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 66, "start_date": "2009-03", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00981526" }, { "nct_id": "NCT00926289", "title": "Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 894, "start_date": "2009-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 18, "location_summary": "Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Lomita", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00926289" }, { "nct_id": "NCT00185705", "title": "Treatment of Insulin Resistance in Hypertensive, Obese Adolescents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension", "Insulin Resistance", "Dyslipidemia" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2006-10", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00185705" }, { "nct_id": "NCT04518306", "title": "Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg", "type": "DRUG" }, { "name": "Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Medicines PTY Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 755, "start_date": "2021-06-14", "completion_date": "2023-10-18", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "South Gate", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518306" }, { "nct_id": "NCT01683084", "title": "Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abdominal Aortic Aneurysm" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palo Alto Veterans Institute for Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 22, "start_date": "2012-09-19", "completion_date": "2018-11-10", "has_results": false, "last_update_posted_date": "2020-05-26", "last_synced_at": "2026-09-24T15:51:02.390Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683084" } ] }